Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 54 | 2024 | 701 | 6.350 |
Why?
|
| Depressive Disorder | 11 | 2017 | 460 | 1.630 |
Why?
|
| Cognition Disorders | 10 | 2022 | 542 | 1.500 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 695 | 1.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2023 | 650 | 1.130 |
Why?
|
| Amnesia | 1 | 2025 | 15 | 0.900 |
Why?
|
| Dissociative Disorders | 1 | 2025 | 13 | 0.890 |
Why?
|
| Anxiety | 12 | 2019 | 964 | 0.850 |
Why?
|
| Prefrontal Cortex | 2 | 2025 | 208 | 0.840 |
Why?
|
| Mental Recall | 1 | 2025 | 137 | 0.840 |
Why?
|
| Psychiatric Status Rating Scales | 13 | 2018 | 822 | 0.800 |
Why?
|
| Aggression | 1 | 2024 | 220 | 0.730 |
Why?
|
| Mental Disorders | 6 | 2016 | 860 | 0.730 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2021 | 15 | 0.720 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 285 | 0.670 |
Why?
|
| Hippocampus | 2 | 2025 | 777 | 0.640 |
Why?
|
| Depression | 16 | 2020 | 1293 | 0.640 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 272 | 0.630 |
Why?
|
| Pituitary Neoplasms | 1 | 2020 | 77 | 0.610 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 189 | 0.600 |
Why?
|
| Dystonia | 2 | 2020 | 162 | 0.500 |
Why?
|
| Cognition | 3 | 2020 | 784 | 0.480 |
Why?
|
| Middle Aged | 40 | 2025 | 27697 | 0.470 |
Why?
|
| Dementia | 3 | 2014 | 416 | 0.440 |
Why?
|
| Psychotic Disorders | 3 | 2019 | 151 | 0.420 |
Why?
|
| Humans | 68 | 2025 | 126753 | 0.400 |
Why?
|
| Panic Disorder | 2 | 2011 | 52 | 0.400 |
Why?
|
| Aged | 33 | 2020 | 20344 | 0.390 |
Why?
|
| Veterans | 5 | 2020 | 1741 | 0.380 |
Why?
|
| Health Services | 1 | 2012 | 67 | 0.380 |
Why?
|
| Surveys and Questionnaires | 9 | 2017 | 3907 | 0.380 |
Why?
|
| Health Status | 2 | 2012 | 380 | 0.380 |
Why?
|
| Illusions | 1 | 2012 | 7 | 0.370 |
Why?
|
| Delusions | 1 | 2012 | 17 | 0.370 |
Why?
|
| Drug Utilization | 1 | 2013 | 163 | 0.370 |
Why?
|
| Hallucinations | 1 | 2012 | 25 | 0.360 |
Why?
|
| Disclosure | 1 | 2013 | 147 | 0.360 |
Why?
|
| Family Health | 3 | 2011 | 248 | 0.360 |
Why?
|
| Nootropic Agents | 2 | 2009 | 27 | 0.350 |
Why?
|
| Male | 45 | 2025 | 62543 | 0.350 |
Why?
|
| Comorbidity | 9 | 2020 | 1559 | 0.330 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 34 | 0.330 |
Why?
|
| Memory Disorders | 3 | 2020 | 207 | 0.330 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 6668 | 0.310 |
Why?
|
| Female | 43 | 2025 | 68330 | 0.310 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.300 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 29 | 0.300 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2014 | 350 | 0.290 |
Why?
|
| Prevalence | 8 | 2020 | 2591 | 0.230 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 2975 | 0.230 |
Why?
|
| Adult | 20 | 2025 | 30410 | 0.230 |
Why?
|
| Memory, Episodic | 1 | 2025 | 27 | 0.230 |
Why?
|
| Psychometrics | 5 | 2013 | 655 | 0.220 |
Why?
|
| Neuropsychological Tests | 8 | 2020 | 951 | 0.210 |
Why?
|
| Indans | 1 | 2004 | 51 | 0.200 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 83 | 0.200 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 3662 | 0.200 |
Why?
|
| Violence | 1 | 2024 | 126 | 0.200 |
Why?
|
| Mental Health Services | 3 | 2015 | 259 | 0.190 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 692 | 0.190 |
Why?
|
| Piperidines | 1 | 2004 | 224 | 0.180 |
Why?
|
| Memory | 3 | 2020 | 346 | 0.180 |
Why?
|
| Patient Health Questionnaire | 1 | 2020 | 16 | 0.170 |
Why?
|
| Attention | 2 | 2020 | 192 | 0.160 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2020 | 9 | 0.160 |
Why?
|
| Internationality | 1 | 2020 | 128 | 0.160 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.160 |
Why?
|
| Unconsciousness | 1 | 2019 | 17 | 0.160 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.160 |
Why?
|
| Dreams | 1 | 2019 | 24 | 0.150 |
Why?
|
| Psychotropic Drugs | 2 | 2011 | 122 | 0.150 |
Why?
|
| Fatigue | 3 | 2010 | 195 | 0.150 |
Why?
|
| Tremor | 1 | 2020 | 130 | 0.150 |
Why?
|
| Encephalitis | 1 | 2020 | 117 | 0.150 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 402 | 0.150 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 238 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 352 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 750 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 96 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 142 | 0.130 |
Why?
|
| Pilot Projects | 4 | 2015 | 1398 | 0.130 |
Why?
|
| Brain Concussion | 1 | 2019 | 230 | 0.130 |
Why?
|
| Public Housing | 1 | 2016 | 7 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 290 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3314 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 227 | 0.120 |
Why?
|
| Dystonic Disorders | 1 | 2017 | 95 | 0.120 |
Why?
|
| Age of Onset | 6 | 2014 | 609 | 0.120 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 152 | 0.120 |
Why?
|
| Psychiatry | 1 | 2019 | 269 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 3262 | 0.120 |
Why?
|
| Apathy | 1 | 2015 | 11 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 249 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 802 | 0.110 |
Why?
|
| Phenotype | 2 | 2017 | 4304 | 0.110 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 9 | 0.110 |
Why?
|
| Heterozygote | 3 | 2014 | 690 | 0.110 |
Why?
|
| Torticollis | 1 | 2014 | 70 | 0.100 |
Why?
|
| Odds Ratio | 3 | 2011 | 1207 | 0.100 |
Why?
|
| ROC Curve | 2 | 2020 | 587 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 143 | 0.100 |
Why?
|
| Research Design | 2 | 2015 | 691 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 3695 | 0.100 |
Why?
|
| Role | 1 | 2013 | 28 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2016 | 413 | 0.100 |
Why?
|
| Mental Health | 2 | 2014 | 363 | 0.100 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 1102 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 320 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2013 | 187 | 0.090 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 2 | 0.090 |
Why?
|
| Dopamine Agents | 1 | 2011 | 28 | 0.090 |
Why?
|
| Independent Living | 1 | 2012 | 62 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 334 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2013 | 263 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 35 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 6214 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 62 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 316 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 466 | 0.080 |
Why?
|
| Database Management Systems | 1 | 2010 | 27 | 0.080 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 37 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2010 | 24 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2010 | 74 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 72 | 0.080 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 26 | 0.080 |
Why?
|
| United States | 6 | 2019 | 11310 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 694 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 15 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2015 | 776 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 196 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2010 | 233 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1166 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2009 | 93 | 0.070 |
Why?
|
| Mutation | 3 | 2010 | 5941 | 0.070 |
Why?
|
| Antiparkinson Agents | 1 | 2009 | 65 | 0.070 |
Why?
|
| Substantia Nigra | 1 | 2008 | 35 | 0.070 |
Why?
|
| alpha-Synuclein | 2 | 2005 | 124 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2010 | 221 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 554 | 0.070 |
Why?
|
| Education | 1 | 2007 | 107 | 0.060 |
Why?
|
| Stroke | 1 | 2014 | 1027 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 4954 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2016 | 12546 | 0.060 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 402 | 0.060 |
Why?
|
| Motivation | 1 | 2008 | 322 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2007 | 1861 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2016 | 950 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 356 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1137 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 355 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 337 | 0.060 |
Why?
|
| Lewy Body Disease | 1 | 2004 | 18 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3066 | 0.050 |
Why?
|
| Consensus | 1 | 2007 | 555 | 0.050 |
Why?
|
| Quality of Life | 4 | 2019 | 2029 | 0.050 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 72 | 0.050 |
Why?
|
| Risk | 2 | 2020 | 729 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2883 | 0.050 |
Why?
|
| Alzheimer Disease | 2 | 2015 | 835 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 1056 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 441 | 0.040 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 77 | 0.040 |
Why?
|
| Huntington Disease | 1 | 2002 | 140 | 0.040 |
Why?
|
| Aging | 1 | 2008 | 1193 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 157 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 2595 | 0.040 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 20 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1584 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 424 | 0.040 |
Why?
|
| Simplexvirus | 1 | 2020 | 98 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10555 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 118 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 126 | 0.040 |
Why?
|
| Vision, Ocular | 1 | 2020 | 124 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 37 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1098 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 737 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 422 | 0.040 |
Why?
|
| Neurons | 1 | 2008 | 1919 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 9665 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2014 | 1193 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 333 | 0.030 |
Why?
|
| Disease Progression | 2 | 2014 | 2109 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2065 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 112 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 534 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 189 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 77 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 427 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 39 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 132 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 136 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 172 | 0.030 |
Why?
|
| Adolescent | 3 | 2020 | 20002 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2015 | 437 | 0.020 |
Why?
|
| Age Factors | 2 | 2010 | 2789 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 182 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 792 | 0.020 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 19 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 482 | 0.020 |
Why?
|
| Carbidopa | 1 | 2011 | 17 | 0.020 |
Why?
|
| Sensation | 1 | 2011 | 48 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 557 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1428 | 0.020 |
Why?
|
| Levodopa | 1 | 2011 | 92 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1377 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1137 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 33 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1309 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 664 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 124 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 118 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 261 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 488 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 759 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 620 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 485 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 781 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 182 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1220 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 428 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 88 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 100 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1364 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1779 | 0.010 |
Why?
|
| Synucleins | 1 | 2004 | 13 | 0.010 |
Why?
|
| Lewy Bodies | 1 | 2004 | 12 | 0.010 |
Why?
|
| Formates | 1 | 2004 | 7 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 602 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2225 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1536 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1508 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 757 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 236 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 17005 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1597 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 4772 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 169 | 0.010 |
Why?
|
| Brain | 1 | 2010 | 3038 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 33051 | 0.000 |
Why?
|